Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Genocea Biosciences, Inc.

A website that provides a comprehensive listing of annual reports for international companies.

msh id	COM:GENOCEA
symbol	GNCA
name	Genocea Biosciences, Inc.
homepage url	https://www.genocea.com
country	US
sector	-
industry	-
market	STOCKS
employee count	74
crunchbase url	-
linkedin url	-
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-1
growth cost of revenue	-
growth depreciation and amortization	-1
growth ebitda	0.17
growth ebitda ratio	0.31
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.02
growth gross profit	-
growth gross profit ratio	-

COM:GENOCEA

AnnualReports.com

Last Close

0.00

22/12 19:54

Volume Today

30.27K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	53.73M
cost of revenue	53.73M
depreciation and amortization	17.78M
ebitda	-34.32M
ebitda ratio	-20.91
eps	-0.22
eps diluted	-0.22
operating expenses	53.73M
operating income	-52.09M
operating income ratio	-31.74

accounts receivables	-
capital expenditure	-3.29M
cash at beginning of period	80.4M
cash at end of period	80.4M
inventory	-
working capital ttm	23.14M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-